Neurophysiological Measures of Sensory Registration, Stimulus Discrimination, and Selection in Schizophrenia Patients

Rissling, Anthony J.; Light, Gregory A.

doi:10.1007/7854_2010_59

Cited by 42 publications

(54 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other prior studies reveal associations between physiological measures and behavioral deficits: (i) both humans (34) and monkeys exhibit schizophrenia-like deficits on task-switching (19) when treated with ketamine; and (ii) the amplitude reduction of MMN has been correlated with behavioral deficits present in schizophrenia patients (1,7), and the reduction of both MMN and P3 has been associated with vulnerability for schizophrenia (8,9). Here, to further explore these relationships and the suitability of the rhesus macaque as an animal model for schizophrenia, we studied the amplitude of MMN and P3a ERP responses in NHPs in relation to the administration of ketamine.…”

Section: Erp Measures Of Disrupted Sensory and Cognitive Function Inmentioning

confidence: 97%

See 1 more Smart Citation

Nonhuman primate model of schizophrenia using a noninvasive EEG method

Gil-da-Costa

Stoner

Fung

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

151

123

View full text Add to dashboard Cite

There is growing evidence that impaired sensory-processing significantly contributes to the cognitive deficits found in schizophrenia. For example, the mismatch negativity (MMN) and P3a event-related potentials (ERPs), neurophysiological indices of sensory and cognitive function, are reduced in schizophrenia patients and may be used as biomarkers of the disease. In agreement with glutamatergic theories of schizophrenia, NMDA antagonists, such as ketamine, elicit many symptoms of schizophrenia when administered to normal subjects, including reductions in the MMN and the P3a. We sought to develop a nonhuman primate (NHP) model of schizophrenia based on NMDA-receptor blockade using subanesthetic administration of ketamine. This provided neurophysiological measures of sensory and cognitive function that were directly comparable to those recorded from humans. We first developed methods that allowed recording of ERPs from humans and rhesus macaques and found homologous MMN and P3a ERPs during an auditory oddball paradigm. We then investigated the effect of ketamine on these ERPs in macaques. As found in humans with schizophrenia, as well as in normal subjects given ketamine, we observed a significant decrease in amplitude of both ERPs. Our findings suggest the potential of a pharmacologically induced model of schizophrenia in NHPs that can pave the way for EEG-guided investigations into cellular mechanisms and therapies. Furthermore, given the established link between these ERPs, the glutamatergic system, and deficits in other neuropsychiatric disorders, our model can be used to investigate a wide range of pathologies.brain | psychiatry | neurology | monkey | medicine S chizophrenia is a multifaceted disorder that may originate from neuronal pathology in multiple brain systems (1). Current theories suggest that some of the sensory and cognitive symptoms of schizophrenia may, at least partially, result from dysfunction of the glutamate neurotransmitter system (2). In support of this theory, it has been found that acute subanesthetic doses of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine induces sensory and cognitive deficits akin to those experienced by schizophrenia patients, as well as decreases of the mismatch negativity (MMN) and P3 event-related potential (ERP) amplitudes (3).The MMN is thought to reflect preattentive detection of a deviant stimulus (4), whereas the P3 is thought to reflect the redirection of attention to that deviant stimulus (5). In an oddball paradigm, responses to deviant (or "oddball") stimuli occurring among a sequence of standard stimuli are measured. The MMN is obtained by subtracting the ERP to the standard stimulus from the ERP to the deviant stimulus, whereas the P3a is typically observed in the ERP to deviants.Schizophrenia patients appear less able to detect and direct attention to novel stimuli than healthy controls (6). Consistent with this behavioral deficit, the amplitudes of both the MMN (7) and the P3 (8) have been found to be reduced in schizophrenia patients, l...

show abstract

Section: Erp Measures Of Disrupted Sensory and Cognitive Function Inmentioning

confidence: 97%

“…brain | psychiatry | neurology | monkey | medicine S chizophrenia is a multifaceted disorder that may originate from neuronal pathology in multiple brain systems (1). Current theories suggest that some of the sensory and cognitive symptoms of schizophrenia may, at least partially, result from dysfunction of the glutamate neurotransmitter system (2).…”

mentioning

confidence: 99%

Nonhuman primate model of schizophrenia using a noninvasive EEG method

Gil-da-Costa

Stoner

Fung

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

151

123

View full text Add to dashboard Cite

show abstract

“…Aberrant behavior may appear particularly in complex tasks, and information processing deficits have been identified for a number of aspects (Rissling & Light, 2010), such as dual-task information processing in visual and auditory continuous performance (Moriarty et al, 2003), in working memory and selective attention (van Raalten, Ramsey, Jansma, Jager, & Kahn, 2008), as well as in performance of dual fine motor tasks (Fuller & Jahanshahi, 1999). In dual paradigms including both cognitive and motor tasks, performance in both domains may be affected as cognitive and motor functions share common neural networks (Chong et al, 2010).…”

mentioning

confidence: 99%

Postural Control In Quiet Standing With A Concurrent Cognitive Task In Psychotic Conditions

Stensdotter¹,

Wanvik²,

Lorås³

2013

Journal of Motor Behavior

View full text Add to dashboard Cite

Differences in postural control and performance between psychotic patients and healthy subjects were investigated using a dual task paradigm. Center of pressure (CoP) data and whole-body kinematics of the center of mass (CoM) were recorded during quiet standing with and without a backward counting task. Dual task response was similar in both groups: the magnitude of CoM-migration did not change, while CoP-CoM magnitude, a measure related to ankle joint torque, and CoP-frequency both increased. The magnitudes of migration for CoM and CoP-CoM were greater in patients during both conditions, while CoP-frequency was similar to control subjects. Our results suggest that exaggerated ankle joint torque relative to CoP-frequency caused greater postural sway in patients during both conditions.

show abstract

“…In addition there is an increasing interest in the use of ERP biomarkers for characterisation of, for example, the cognitive disturbances in schizophrenia [124] or clinical depression [125]. …”

Section: Pharmaco-eeg – Advanced Topicsmentioning

confidence: 99%

Guidelines for the Recording and Evaluation of Pharmaco-EEG Data in Man: The International Pharmaco-EEG Society (IPEG)

Jobert¹,

Wilson

Ruigt³

et al. 2012

Neuropsychobiology

145

132

View full text Add to dashboard Cite

The International Pharmaco-EEG Society (IPEG) presents updated guidelines summarising the requirements for the recording and computerised evaluation of pharmaco-EEG data in man. Since the publication of the first pharmaco-EEG guidelines in 1982, technical and data processing methods have advanced steadily, thus enhancing data quality and expanding the palette of tools available to investigate the action of drugs on the central nervous system (CNS), determine the pharmacokinetic and pharmacodynamic properties of novel therapeutics and evaluate the CNS penetration or toxicity of compounds. However, a review of the literature reveals inconsistent operating procedures from one study to another. While this fact does not invalidate results per se, the lack of standardisation constitutes a regrettable shortcoming, especially in the context of drug development programmes. Moreover, this shortcoming hampers reliable comparisons between outcomes of studies from different laboratories and hence also prevents pooling of data which is a requirement for sufficiently powering the validation of novel analytical algorithms and EEG-based biomarkers. The present updated guidelines reflect the consensus of a global panel of EEG experts and are intended to assist investigators using pharmaco-EEG in clinical research, by providing clear and concise recommendations and thereby enabling standardisation of methodology and facilitating comparability of data across laboratories.

show abstract

Neurophysiological Measures of Sensory Registration, Stimulus Discrimination, and Selection in Schizophrenia Patients

Cited by 42 publications

References 182 publications

Nonhuman primate model of schizophrenia using a noninvasive EEG method

Nonhuman primate model of schizophrenia using a noninvasive EEG method

Postural Control In Quiet Standing With A Concurrent Cognitive Task In Psychotic Conditions

Guidelines for the Recording and Evaluation of Pharmaco-EEG Data in Man: The International Pharmaco-EEG Society (IPEG)

Contact Info

Product

Resources

About